. Overview Historically, we have been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, we announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that we were exploring strategic alternatives to maximize stockholder value. In February 2024, we received an upfront payment of $500,000 from a licensing agreement for paten...
expected 2026-12-16
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-25 | 2025-12-31 | 0001698530-26-000028 | EDGAR | 44K words |
| 2025-03-18 | 2024-12-31 | 0001698530-25-000019 | EDGAR | 42K words |
| 2024-06-06 | 2023-12-31 | 0001698530-24-000051 | EDGAR | 51K words |
| 2023-03-27 | 2022-12-31 | 0001698530-23-000029 | EDGAR | 53K words |
| 2022-03-25 | 2021-12-31 | 0001698530-22-000019 | EDGAR | — |
| 2021-03-11 | 2020-12-31 | 0001698530-21-000031 | EDGAR | — |
| 2020-03-10 | 2019-12-31 | 0001698530-20-000013 | EDGAR | — |
| 2019-03-08 | 2018-12-31 | 0001698530-19-000015 | EDGAR | — |
| 2018-03-09 | 2017-12-31 | 0001698530-18-000007 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-14 | 2026-06-30 | 0001193125-26-352011 | EDGAR | 19K words |
| 2025-11-07 | 2025-09-30 | 0001698530-25-000100 | EDGAR | 18K words |
| 2025-08-08 | 2025-06-30 | 0001698530-25-000077 | EDGAR | 18K words |
| 2025-06-27 | 2025-03-31 | 0001698530-25-000056 | EDGAR | 18K words |
| 2024-11-14 | 2024-09-30 | 0001698530-24-000117 | EDGAR | 27K words |
| 2024-08-13 | 2024-06-30 | 0001698530-24-000089 | EDGAR | 25K words |
| 2024-06-17 | 2024-03-31 | 0001698530-24-000068 | EDGAR | 24K words |
| 2024-05-16 | 2023-09-30 | 0001698530-24-000030 | EDGAR | 27K words |
| 2023-08-11 | 2023-06-30 | 0001698530-23-000091 | EDGAR | 34K words |
| 2023-07-14 | 2023-03-31 | 0001698530-23-000079 | EDGAR | 33K words |
| 2022-11-14 | 2022-09-30 | 0001698530-22-000088 | EDGAR | 46K words |
| 2022-08-15 | 2022-06-30 | 0001698530-22-000058 | EDGAR | 59K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-16 | 0001193125-26-392654 | EDGAR | 0K words |
| 2026-04-02 | 0001698530-26-000034 | EDGAR | 14K words |
| 2026-03-27 | 0001698530-26-000031 | EDGAR | 0K words |
| 2026-03-25 | 0001698530-26-000026 | EDGAR | 2K words |
| 2026-02-17 | 0001698530-26-000013 | EDGAR | 1K words |
| 2026-02-10 | 0001698530-26-000009 | EDGAR | 1K words |
| 2026-01-22 | 0001698530-26-000007 | EDGAR | 1K words |
| 2025-11-17 | 0001698530-25-000105 | EDGAR | 1K words |
| 2025-11-10 | 0001698530-25-000102 | EDGAR | 1K words |
| 2025-11-07 | 0001698530-25-000099 | EDGAR | 2K words |
229 total filings indexed. 198 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001698530 |
| Ticker | XCUR |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.exicuretx.com |
| Listed | 2018-05-09 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/XCUR (~200 tokens, structured JSON with cryptographic provenance)